Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOPHYLLIN vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of bronchial asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is 7-9 hours in healthy adults; increases to 20-30 hours in congestive heart failure, cirrhosis, or severe COPD; decreases to 3-5 hours in smokers (tobacco or marijuana) due to enzyme induction.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal excretion of unchanged drug accounts for approximately 10% of elimination; hepatic metabolism accounts for 90%, with metabolites excreted in urine. Biliary/fecal excretion is negligible (<2%).
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40% bound to albumin; binding is nonlinear and decreases at higher serum concentrations.
Approximately 70% bound to plasma proteins, primarily albumin.
0.4-0.7 L/kg, approximating total body water (0.45 L/kg in adults). Vd is increased in neonates (0.6 L/kg) and decreased in obesity (0.3-0.4 L/kg) due to reduced lean body mass.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 90-100%; Oral sustained-release: 80-100% relative to immediate-release; Rectal solution: 100%; Rectal suppository: 60-80% (erratic).
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
For GFR <30 m L/min: reduce maintenance dose by 50%; consider monitoring serum concentrations.
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 75%; Child-Pugh Class C: avoid use or use with extreme caution with 80% dose reduction.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
IV loading dose: 5-7 mg/kg over 20-30 minutes; maintenance IV infusion: 0.5-1 mg/kg/hour for ages 1-9 years, 0.4-0.7 mg/kg/hour for ages 9-16 years; oral: 10-20 mg/kg/day in divided doses every 6-8 hours, maximum 600 mg/day.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Elderly patients: reduce loading dose to 4-5 mg/kg; maintenance dose 0.2-0.3 mg/kg/hour IV or 200-400 mg/day oral; monitor serum theophylline levels closely due to decreased clearance.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
None explicitly required by FDA, but use with caution due to narrow therapeutic index and potential for severe toxicity.
None.
Narrow therapeutic index; monitor serum concentrations regularly. Risk of arrhythmias, seizures, and gastrointestinal bleeding. Use lower doses in heart failure, liver disease, and elderly. Avoid abrupt discontinuation due to withdrawal symptoms.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to xanthines, active seizure disorders, severe arrhythmias, and uncontrolled hyperthyroidism.
Hypersensitivity to theophylline or any component of the formulation.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition increasing theophylline levels. Limit caffeine intake (coffee, tea, cola) as it may add to theophylline's stimulant effects. High-fat meals may delay absorption; take consistently with or without food.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third trimesters: no known adverse fetal effects. However, use only if clearly needed.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Excreted into breast milk; M/P ratio approximately 0.6-0.8. Relative infant dose is low (<10% of maternal weight-adjusted dose). No reports of adverse effects in breastfed infants. Caution advised in preterm or ill infants.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy reduces theophylline clearance by 30-50%, especially in the third trimester. Dose may need reduction by up to 50% to maintain therapeutic levels. Monitor levels closely and adjust accordingly. Postpartum clearance rapidly returns to prepregnancy levels, requiring dose increase to avoid subtherapeutic levels.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
LANOPHYLLIN is a fixed-dose combination of lansoprazole, a proton pump inhibitor, and theophylline, a methylxanthine bronchodilator. Monitor serum theophylline levels due to lansoprazole's potential to inhibit CYP1A2, increasing theophylline toxicity risk. Avoid in patients with hepatic impairment or acute asthma exacerbation. Taper theophylline to prevent withdrawal seizures.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take this medication exactly as prescribed, usually once daily in the morning.,Swallow the capsule whole; do not crush or chew.,Avoid drinking alcohol or consuming grapefruit products while on this medication.,Report symptoms like nausea, vomiting, palpitations, or seizures immediately.,Do not stop abruptly; consult your doctor for gradual dose reduction.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOPHYLLIN vs AEROLATE JR, answered by our medical review team.
LANOPHYLLIN is a Bronchodilator that works by Lanophyllin is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation, respiratory stimulation, and anti-inflammatory effects.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOPHYLLIN and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOPHYLLIN is: 5-6 mg/kg IV loading dose over 20-30 minutes, then 0.4-0.6 mg/kg/hour continuous IV infusion; maintenance oral dose 300-600 mg/day in divided doses every 8-12 hours.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOPHYLLIN and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOPHYLLIN is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. First trimester: no known increase in major malformations. Second and third. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.